Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Oct 16, 2026
LABX: Analyzing the +34% Rally in Tradr's 2X Long ALAB Daily ETF

LABX: Analyzing the +34% Rally in Tradr's 2X Long ALAB Daily ETF

Key Takeaways

  • LABX is a leveraged single-stock ETF that seeks 200% of the daily return of ALAB, the common shares of semiconductor-connectivity company Astera Labs.
  • The fund climbed roughly 34% over the last 30 days, from about $7.85 to $10.52, on exceptionally choppy, high-volume trading.
  • The rebound was driven by Astera Labs' strong third-quarter revenue guidance, the ramp of its Scorpio AI fabric switches and Aries PCIe 6 retimers, and renewed AI-infrastructure enthusiasm.
  • Despite the rally, LABX remains well below levels from roughly three months earlier, reflecting the volatility drag and compounding effects of daily-reset leverage.
  • LABX is a non-diversified, actively managed fund with an expense ratio of about 1.30% and is designed for short-term trading rather than buy-and-hold investing.

Tradr 2X Long ALAB Daily ETF (LABX) Overview and Portfolio Exposure

The Tradr 2X Long ALAB Daily ETF, launched in August 2025 and managed by Tradr, a brand of AXS Investments, seeks daily investment results of two times the daily performance of Astera Labs common shares. Astera Labs designs semiconductor-based connectivity solutions—including PCIe and CXL retimers, fabric switches, and smart cable modules—for cloud and AI data-center infrastructure.

Unlike a diversified sector fund, LABX concentrates its exposure in a single underlying stock using derivatives and swap agreements rather than a broad basket of securities. The fund reports only a handful of portfolio positions, with gross exposure exceeding 100% of net assets to achieve its 2x objective (domestic equity exposure is approximately 113.6% of assets, offset by negative cash). This structure is materially different from a conventional index ETF and produces amplified daily moves in both directions. I also checked this using Tickeron’s AI Screener to see how the fund compares to other leveraged products in the sector.

The fund carries an expense ratio of approximately 1.30%, roughly $80 million in assets under management (AUM), and is classified as non-diversified. Because it rebalances exposure daily, its returns over periods longer than a single trading day will diverge from two times Astera Labs' cumulative return—a core risk embedded in its design.

LABX Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, LABX advanced approximately 34%, rising from a close near $7.85 to $10.52. The move was far from linear: the fund recorded multiple double-digit percentage swings within the period as Astera Labs shares rallied and then pulled back.

The trailing quarter tells a different story. From a level near $14.81 in mid-July, LABX is down roughly 29% through mid-October despite the recent bounce. This divergence between the 30-day and three-month figures underscores the path-dependence of leveraged daily-reset products—sharp rallies can occur even while a fund remains below prior highs because of volatility decay and the compounding of daily returns.

What Drove LABX Price in the Last 30 Days

The 30-day advance was primarily a reflection of strength in ALAB, which gained roughly 20% over the same window, with LABX amplifying that move through its 2x daily leverage. Astera Labs issued third-quarter revenue guidance of approximately $540 million to $560 million, implying sequential growth of roughly 40%, as its Scorpio AI fabric switches moved toward becoming its largest product family and its Aries PCIe 6 retimers delivered record revenue.

Product announcements reinforced sentiment. The company unveiled its Aries 7 PCIe 7 signal-conditioning portfolio and participated in demonstrations—including PCIe-over-optics work with Lumentum and Corning—at an industry summit focused on AI rack-scale connectivity. These developments positioned Astera Labs as a direct beneficiary of hyperscaler spending on AI data centers.

The period also showed the fund's downside sensitivity. Late in the window, Astera Labs shares pulled back after an analyst downgrade citing valuation and broader concerns tied to AI-spending assumptions, with the stock declining roughly 9% in a single session. That reversal produced a correspondingly sharp drop in LABX, illustrating how quickly leveraged single-stock exposure can unwind. From what I see, reviewing these moves with Tickeron’s AI Trend Prediction Engine helped clarify the momentum shifts.

What Drove LABX Performance Over the Last Quarter

Across the trailing three months, LABX's decline reflects two reinforcing forces. First, Astera Labs shares themselves corrected from their late-summer highs, weighed down by valuation sensitivity in high-multiple connectivity names and periodic investor unease about the durability of AI capital spending. Second, the daily-reset 2x structure suffered from volatility decay during a period of unusually wide swings, which erodes value even when the underlying stock does not move decisively in one direction.

Competitive dynamics also played a role. Investors weighed Astera Labs against established connectivity and networking suppliers such as MRVL, while rotating among AI-infrastructure names as sentiment around data-center buildouts shifted. These structural and positioning factors, more than any single news event, shaped the fund's broader three-month trend.

LABX ETF Outlook: What Investors Should Watch Next

Several factors are likely to shape LABX over the coming months. Astera Labs' quarterly earnings report and its commentary on the Scorpio ramp, gross-margin mix, and customer concentration will be pivotal, given how sensitive the shares are to execution and guidance. Broader AI-infrastructure capital spending by hyperscalers, along with the pace of PCIe 6 and PCIe 7 adoption, will influence demand for the company's connectivity products.

Macroeconomic conditions also matter. Interest-rate expectations and inflation trends affect the valuation of high-multiple growth and semiconductor names, while any reassessment of AI-spending assumptions can trigger rapid repricing. Investors should additionally monitor the structural risks unique to LABX itself: daily-reset leverage, volatility decay, rebalancing costs, and the liquidity of a relatively small single-stock fund. These characteristics make LABX appropriate primarily for experienced traders with a short-term horizon and active risk management, rather than long-term investors seeking diversified exposure. I'm watching this closely as earnings season approaches.

Exploring Tickeron’s AI Screener for Leveraged ETF Research

In my own analysis of products like LABX, Tickeron’s AI Screener has become a useful part of the workflow. It allows quick scans across technical indicators, fundamentals, volatility metrics, and industry filters to identify comparable leveraged instruments or monitor momentum changes. The platform helps surface ideas that align with specific performance characteristics, which can be especially helpful when evaluating single-stock ETFs amid sector swings. This kind of tool supports more efficient research without replacing careful review of the underlying risks.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: LABX

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


LABX's RSI Indicator recovers from overbought zone

The 10-day RSI Oscillator for LABX moved out of overbought territory on October 07, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 instances where the indicator moved out of the overbought zone. In 8 of the 8 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LABX as a result. In 20 of 20 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for LABX turned negative on October 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 11 similar instances when the indicator turned negative. In 11 of the 11 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

LABX moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LABX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for LABX crossed bullishly above the 50-day moving average on September 25, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 3 of 3 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +22.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where LABX advanced for three days, in 69 of 72 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

LABX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 55 of 60 cases where LABX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Industry description

The investment seeks daily investment results, before fees and expenses, that correspond to two times (200%) the daily performance of the common shares of ALAB. Under normal market circumstances, the fund will maintain at least 80% exposure to financial instruments that provide two times leveraged exposure to the daily performance of ALAB. The Advisor attempts to consistently apply leverage to increase the fund’s exposure to 200% of ALAB, and expects to rebalance the fund’s holdings daily to maintain such exposure. The fund is non-diversified.
View a ticker or compare two or three
LABX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Leveraged Equity
Address
Investment Managers Series Trust II803 West Michigan StreetMilwaukee
Phone
(414) 299-2295
Web
N/A
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.
AMD (Advanced Micro Devices) designs central processing units (CPUs), graphics processing units (GPUs), and AI accelerators, while LRCX (Lam Research) supplies the wafer-fabrication equipment used to build advanced chips. AMD has delivered strong double-digit revenue growth on AI data-center demand, but its shares trade with elevated expectations that can trigger sharp reactions around earnings.
Origination momentum: Velocity Financial enters 2026 off record annual originations of roughly $2.7 billion (up about 48%), positioning it to keep gaining share in a fragmented investor-loan market. Credit normalization is the central watch item: Nonperforming loans fell toward the 8.5% range of portfolio unpaid principal balance (UPB), but asset quality remains the primary swing factor for earnings.
Turnaround milestone ahead: Management has pointed to reaching cash generation in 2027, making the pace of cost discipline and margin recovery the central question for the stock forecast. Fresh capital supports execution: A recently announced $45.5 million equity financing, with participation from management and a single institutional investor, strengthens the balance sheet as the company funds its transformation.
NFE closed at $5.51, down -6.13% during Tuesday's regular session, extending a slide that has pushed shares near a 52-week low. Primary catalyst: the company disclosed its Fast LNG unit is offline after a gas-turbine mechanical failure, with return to service not expected until Q4.
The central $11 target is the arithmetic mean of four verified analyst price targets, rounded from roughly $10.75. With the stock near $2.06, reaching $11 would require an upside of more than 400%, an extremely large move.
The $23 central target is the rounded arithmetic mean of four verified analyst price targets, which average $23.25. The latest verified price is around $9.57, meaning the target implies roughly 140% upside—a very large move.
NXH closed down -11.17% (-$0.23) to $1.83 on Oct 6, the most recent regular session, extending a steep two-day decline. Selling continued as investors digested the mutual termination of the Fathom Holdings merger and a dilutive $45.5M registered direct offering of ~16.5M shares at $2.76.
AMD is a large-cap designer of CPUs (central processing units) and GPUs (graphics processing units) competing directly with Nvidia in the AI accelerator market, while FORM is a small-cap provider of semiconductor test and measurement equipment, primarily probe cards. AMD's narrative has been driven by multi-billion-dollar hyperscaler deals, while FORM's has been powered by record revenue and sharp margin expansion tied to high-bandwidth memory (HBM) demand.
AMD has surged roughly 200% year to date, crossing a $1 trillion market capitalization on AI data-center demand and a "CPU renaissance" narrative. KLAC has gained about 71% year to date, supported by record process-control revenue and rapid growth in advanced packaging for AI chips.
AMD is a large-cap semiconductor designer riding explosive AI compute demand, while ENTG is a mid-cap supplier of materials and purity solutions that feed the same AI-driven chip cycle. AMD recently crossed a $1 trillion market capitalization on surging data center revenue, whereas ENTG operates at a far smaller scale (roughly $23 billion) with steadier, double-digit growth.
VELO closed Tuesday at $9.57, unchanged (+0.00%) from the prior session, with the move occurring during regular market hours. The flat close marked stabilization after Monday's -14.5% plunge, when shares fell to $9.57 from $11.20 following disclosure of CFO James Suva's departure.
The $8 target used here is a technical, publicly discussed recovery objective — not an analyst consensus — because legacy analyst price targets were set before NFE's restructuring and reverse stock split. New Fortress Energy Inc. ( NFE ) trades near $5.51, so reaching $8 implies a roughly 45% advance.
AVBP plunged -46.98% during Tuesday's regular session, closing at $15.09 versus $28.46, marking its worst single-day decline on record. The catalyst was the Phase 3 FURVENT trial of firmonertinib failing its primary endpoint—progression-free survival—in first-line EGFR exon 20 insertion non-small cell lung cancer.
Upcoming catalyst: The company's next earnings release is estimated for November 6, 2026, which should offer fresh detail on its SKY token holdings, staking rewards, and treasury strategy. Strategic positioning: SDEV is an on-chain holding company providing public-market exposure to the Sky protocol ecosystem, with SKY as its core digital asset and a stated focus on the stablecoin economy.
Different roles in the chip ecosystem: AMAT is a materials-engineering and deposition leader, while KLAC dominates process control, inspection, and yield management. Momentum favors AMAT: AMAT shares have more than doubled this year, while KLAC has recently pulled back roughly 9% in a month on margin and execution concerns.